不同剂量的mRNA-1345 (50ug、100ug及200ug)在两组人群中具有相当的免疫原性,相比安慰剂组,均可触发明显的针对RSV-A/B的中和抗体滴度。 数据来源:Safety and Immunogenicity of mRNA-1345, an mRNA-Based RSV Vaccine in Younger and Older Adult Cohorts: Results from a Phase 1, Randomized Clinical Trial. ...
参考文献: Gatt D, Martin I, AlFouzan R, Moraes TJ. Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV). Pathogens. 2023 Jan 17;12(2):154. doi: 10.3390/pathogens12020154. PMID: 36839426; PMCID: PMC9961958. Azzari C, Baraldi E, Bonanni P, Bozzola E, Coscia A, Lan...
The Moderna COVID-19 vaccine 2024-2025 Formula is an mRNA COVID-19 vaccine that may help your child develop immunity to SARS-CoV-2, the virus that causes COVID-19. The Moderna COVID-19 vaccine has been granted Emergency Use Authorization (EUA) for childr
Respiratory syncytial virus (RSV) vaccine for older adults (mRNA-1777 and mRNA-1172 or V172 with Merck) 针对老年人的人类唿吸道合胞病毒(RSV)疫苗(mRNA-1777和 mRNA-1172或默克公司的 V172) RSV vaccine for young children (mRNA-1345) 儿童呼吸道合胞病毒疫苗(mRNA-1345) Human metapneumovirus (hM...
Moderna also has tested the vaccine in 12- to 17-year-olds but hasn’t yet released the findings. Researchers started with older children because they tend to respond to vaccines most similarly to adults. The study in younger children will be more complex because scientists need to determine ...
Respiratory syncytial virus (RSV) vaccine for older adults (mRNA-1777 and mRNA-1172 or V172 with Merck) RSV vaccine for young children (mRNA-1345) Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) vaccine (mRNA-1653) Novel coronav...
Expects regulatory approvals for its investigational RSV vaccine for older adults beginning in first half of 2024, and anticipates additional key milestones from its late-stage pipeline this year CAMBRIDGE, MA / ACCESSWIRE / February 22, 2024 / Moderna, Inc. (NASDA...
“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our ...
Cavaleri said the Moderna shot was also being recommended for use as a booster dose in people who had received other vaccines. Children had previously been given the Pfizer/BioNTech vaccine, which was the only vaccine EMA had approved for children aged five and over. ...
Spikevax(COVID-19 Vaccine, mRNA) isapprovedfor use in individuals 12 years of age and older. Moderna COVID-19 Vaccineisauthorizedunder an Emergency Use Authorization (EUA)in individuals 6 months through 11 years of age. The EUA for this product is in effect for the duration of the COVID-...